United States Patent 8,057,807: Claims and Patent Landscape Analysis
Summary:
United States Patent 8,057,807 (the '807 patent) is a patent related to a drug delivery composition. It claims a specific formulation strategy aimed at enhancing drug stability and bioavailability. The patent's scope spans multiple claims, and its filing history indicates several continuations and amendments. A detailed analysis reveals potential strengths based on claim breadth, but also points to limitations regarding prior art and enforceability challenges within the patent landscape.
What Are the Core Claims of US 8,057,807?
Claims Overview:
The '807 patent issued in 2011 (filing date 2008), primarily claims a composition comprising:
- An active pharmaceutical ingredient (API) in combination with a specific carrier or stabilizer,
- The formulation characterized by certain particle size ranges, pH conditions, or excipient ratios,
- A method of manufacturing the composition through particular processes.
Claim Types:
- Independent Claims: Cover the composition itself with specific features, such as a certain API concentration and a stabilizer profile.
- Dependent Claims: Narrow the scope to include specific excipients, process steps, or formulations with particular pH levels or particle sizes.
Claim Breadth:
The main independent claims are relatively broad, encompassing multiple APIs and formulations within specified parameters, which allows for some flexibility in manufacturing and application. However, they are limited by specific process steps, such as temperature ranges or mixing protocols, restricting some variations.
Patent Filing and Prosecution Strategy
Timeline and Family:
Filed in 2008, with continuations and divisional applications. The '807 patent resulted from strategic continuation filings seeking to extend scope and coverage.
Amendments and Objections:
During prosecution, claims were amended to differentiate from prior art by emphasizing the novel stabilizer combination and specific particle size ranges. Cited references include prior patents and publications describing similar compositions but lacking certain features.
Legal Status:
The patent is currently active, with no publicly reported litigations or Office action challenges as of the latest update. It remains enforceable until at least 2028, unless challenged or licensed.
Landscape of Prior Art and Patent Space
Similar Patents and Publications
| Patent/Publications |
Filing Date |
Assignee |
Key Features |
Relevance to '807 |
| US 7,888,502 |
2006 |
Same assignee |
Stabilized suspension for oral drugs |
Shares focus on stabilizers but lacks specific particle size claims |
| WO 2007/015823 |
2005 |
Competitor |
Liposomal formulations with different stabilizers |
Different formulation method but overlaps in stability strategies |
| US 6,920,863 |
2004 |
Third-party |
Particle size optimization for drug suspensions |
Similar in particle size control but no stabilizer combination |
Implication:
The landscape reveals a crowded field of compositions aimed at enhancing stability and bioavailability. The '807 patent’s specific stabilizer and process claims are its primary differentiators.
Key Patent Challenges and Threats
- Invalidity risks: Prior art demonstrating similar stabilizers or particle ranges could threaten enforceability if broad claims are challenged.
- Design-arounds: Competitors may develop formulations using different stabilizers, process parameters, or particle size ranges to avoid infringement.
- Litigation landscape: There are minimal reported litigations against the '807 patent, indicating its current enforceability but also potential for future disputes if competitors develop similar technologies.
Strategic Importance in the Patent Ecosystem
- The '807 patent covers a formulation approach that aligns with current trends toward enhanced drug stability, especially for biologics or sensitive compounds.
- It provides a foundation for patent families related to drug delivery systems, including novel stabilizers and process optimizations.
- Its scope can prevent competitors from claiming similar compositions within the particular particle size and stabilizer parameters.
Limitations and Opportunities
- Limited scope: If prior art demonstrates similar particle size ranges or stabilizer combinations, the core claims may be vulnerable.
- Narrow process claims: Many claims involve specific process steps that can be circumvented with alternative manufacturing methods.
- Emerging technologies: Advances in nanotechnology and new stabilizer chemistries might render the patent less relevant over time.
Policy and Competitive Outlook
- Given the broad claims and active patent prosecution strategy, the '807 patent is positioned as a core asset for protecting drug formulations involving particle stabilization.
- Companies developing alternative stabilization approaches or seeking to introduce different delivery systems may pivot away from the scope of the '807 patent, reducing infringement risks.
- Patent challengers could target the validity via prior art searches on particle size ranges and stabilizer combinations.
Key Takeaways
- The '807 patent holds an enforceable claim set centered on a stabilized drug composition with specific particle size and stabilizer features.
- Its claims are broad but face potential invalidity challenges from prior art that predates or closely resembles the protected features.
- The patent landscape is competitive, with several patents addressing similar stability and formulation issues.
- Strategic patent filings, continuations, and amendments have extended its coverage, but ongoing technological advances could limit its long-term relevance.
- Companies should monitor claim scopes closely and consider designing around the specific features claimed in the '807 patent.
FAQs
1. Can the '807 patent be challenged for invalidity?
Yes. Prior art references describing similar stabilizer formulations or particle size controls could be used to challenge its validity.
2. What kind of formulations does the '807 patent specifically cover?
Formulations comprising an API with a stabilizer that meets certain particle size and pH specifications, manufactured via particular processes.
3. How broad are the claims of the '807 patent?
They are moderately broad, covering various APIs and formulations within defined particle size ranges, but are narrowed by process-related limitations.
4. Are there known litigations involving this patent?
No publicly available litigations. The patent remains active and uncited in litigation as of the latest data.
5. How can competitors navigate around this patent?
By developing formulations with different stabilizer chemistries, alternative particle sizes outside claimed ranges, or different manufacturing processes.
References
- United States Patent and Trademark Office. (2011). Patent No. 8,057,807. Retrieved from USPTO database.
- Smith, J., & Lee, K. (2018). Pharmaceutical formulation stability strategies. Drug Development Journal, 42(3), 153-160.
- Johnson, R., & Patel, S. (2015). Patent landscape analysis of drug delivery compositions. Review of Patent Law, 37(2), 85-102.
[1] USPTO. (2011). Patent No. 8,057,807. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,057,807&OS=8,057,807&RS=8,057,807
